Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Gastric Cancer
•
Medical Oncology
•
MD Anderson
•
NCI-CCC Tumor Board Question
•
NCI-CCC GI Tumor Board Question
How do you approach neoadjuvant/adjuvant therapy in MSI-H locally advanced gastric cancer without an opportunity to enroll in a clinical trial?
Related Questions
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
How do you counsel patients on imaging findings after liver SBRT for HCC, particularly with regard to expectations on timing to tumor resolution?
Would you ever consider adjuvant chemotherapy for a patient with rectal cancer treated with RAPIDO total neoadjuvant therapy after positive PNI was found on the surgery?
Do you modify the dose of Naliri in Nalirifox for patient that are heterozygous for UGT1A1 mutations?
Which GI cancer patients do you use oral contrast in staging CT scans?
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?
After the MAJESTEC-3 results, and once approved, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?
Do you incorporate the ALASCCA trial into your clinical practice and perform NGS on all early stage colon cancer patients to determine if adjuvant aspirin would be beneficial?
Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
